1-甲基-3-丙基咪唑甲基碳酸酯 | 1257844-93-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-甲基-3-丙基咪唑甲基碳酸酯
• 英文名称: Methyl carbonate;1-methyl-3-propylimidazol-1-ium
• CAS: 1257844-93-1
• 化学式: C9H16N2O3
• 分子量: 200.23
• InChiKey: ABSPGMJUOBVQMZ-UHFFFAOYSA-M

物化性质

• 闪点：
  26 °C

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] ESLICARBAZEPINE ACETATE AND ITS POLYMORPHS<br/>[FR] ACÉTATE D'ESLICARBAZÉPINE ET SES POLYMORPHES
  申请人：REDDYS LAB LTD DR

  公开号：WO2011091131A2

  公开（公告）日：2011-07-28

  Processes for the preparation of eslicarbazepine acetate and intermediates thereof. Also provided are polymorphic forms of eslicarbazepine acetate and methods for their preparation.

  制备艾司卡巴嗪乙酸酯及其中间体的过程。还提供了艾司卡巴嗪乙酸酯的多态形式及其制备方法。
• Liquid protein formulations containing 4-(3-butyl-1-imidazolio)-1-butane sulfonate (BIM)
  申请人：Eagle Biologics, Inc.

  公开号：US10821183B2

  公开（公告）日：2020-11-03

  Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.

  目前已开发出浓缩、低粘度、低容量的液体蛋白质药物制剂。这些制剂可以通过皮下注射或肌肉注射快速方便地给药，而不需要长时间的静脉注射。这些制剂包括低分子量和/或高分子量蛋白质（如 mAbs）以及降粘离子液体。
• Process for preparing high-reactivity isobutene homo- or copolymers
  申请人：BASF SE

  公开号：US10975175B2

  公开（公告）日：2021-04-13

  The present invention relates to a novel process for preparing high-reactivity isobutene homo- or copolymers with a content of terminal vinylidene double bonds per polyisobutene chain end of at least 70 mol %. The present invention further relates to novel isobutene polymers.

  本发明涉及一种制备高活性异丁烯均聚物或共聚物的新工艺，其每个聚异丁烯链端的末端亚乙烯基双键含量至少为 70 摩尔%。本发明还涉及新型异丁烯聚合物。
• Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
  申请人：EAGLE BIOLOGICS, INC.

  公开号：US11471479B2

  公开（公告）日：2022-10-18

  Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of polysaccharides and nucleic acids have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight polysaccharides and nucleic acids, and viscosity-lowering agents.

  多糖和核酸的浓缩、低粘度、低容量液体药物制剂已经研制成功。这些制剂可以通过皮下注射或肌肉注射快速方便地给药，而不需要长时间的静脉注射。这些制剂包括低分子量和/或高分子量的多糖和核酸以及降粘剂。
• IMIDAZOLIUMSALZE ALS ADDITIVE FÜR KRAFT- UND BRENNSTOFFE
  申请人：BASF SE

  公开号：EP2812418A1

  公开（公告）日：2014-12-17